Skip to content

Public FDA record

Z-0815-2024: DiaSorin LIAISON HSV-2 Type Specific IgG, REF 310620

Recall record Z-0815-2024 for Diasorin Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0815-2024
Company in FDA record
Diasorin Inc.
FDA classification date
Jan 25, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

DiaSorin has identified that lots 136344, 136344A, 136344B, 136344C, 136520, 136520A, 136520B, 136520C, 136604, 136703, 136703A, 136703B, 136703C 136775of LIAISON HSV-2 Type Specific IgG assay may produce increased equivocal and/or false positive results.

Source facts

Action
DiaSorin issued a DIASORIN CUSTOMER NOTIFICATION LETTER to its consignees on 12/13/2023 via email. The notice explained the issue, risk to health, and requested the disposal of all affected inventory. The firm will be providing replacement kits.
Initiated
2023-12-13
Root cause
Under Investigation by firm
Distribution
Worldwide distribution - US Nationwide and the country of Canada.
Recall number
Z-0815-2024
Recall status
Open, Classified
CDRH record ID
205347
FDA classified
2024-01-25
Recall event number
93741

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗